Literature DB >> 33410355

Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis.

Giovanni Palladini1, Stefan O Schönland2, Vaishali Sanchorawala3, Shaji Kumar4, Ashutosh Wechalekar5, Ute Hegenbart2, Paolo Milani1, Yukio Ando6, Per Westermark7, Angela Dispenzieri4, Giampaolo Merlini1.   

Abstract

Entities:  

Year:  2021        PMID: 33410355     DOI: 10.1080/13506129.2020.1868810

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


× No keyword cloud information.
  11 in total

Review 1.  Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.

Authors:  Hannah A Blair
Journal:  Drugs       Date:  2022-04       Impact factor: 9.546

Review 2.  Comprehensive Review of AL amyloidosis: some practical recommendations.

Authors:  Rama Al Hamed; Abdul Hamid Bazarbachi; Ali Bazarbachi; Florent Malard; Jean-Luc Harousseau; Mohamad Mohty
Journal:  Blood Cancer J       Date:  2021-05-18       Impact factor: 11.037

3.  Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis.

Authors:  Lisa Mendelson; Vaishali Sanchorawala; Lawreen Connors; Tracy Joshi; Gheorghe Doros; Alexander Pogrebinsky; Andrea Havasi
Journal:  Kidney Med       Date:  2022-02-03

4.  [Efficacy and safety of daratumumab in the treatment of advanced light chain amyloidosis].

Authors:  K N Shen; H L Miao; Y J Gao; X X Cao; D B Zhou; W Su; J Li
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-01-14

5.  Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis.

Authors:  Gareth J Morgan; Joel N Buxbaum; Jeffery W Kelly
Journal:  Hemato       Date:  2021-10-05

6.  Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group.

Authors:  Andrea Havasi; Cihan Heybeli; Nelson Leung; Avital Angel-Korman; Vaishali Sanchorawala; Oliver Cohen; Ashutosh Wechalekar; Frank Bridoux; Insara Jaffer; Victoria Gutgarts; Hani Hassoun; Maya Levinson; Cara Rosenbaum; Paolo Milani; Giovanni Palladini; Giampaolo Merlini; Ute Hegenbart; Stefan Schönland; Kaya Veelken; Alexander Pogrebinsky; Gheorghe Doros; Heather Landau
Journal:  Blood Cancer J       Date:  2022-08-18       Impact factor: 9.812

7.  Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.

Authors:  Sriram Ravichandran; Oliver C Cohen; Steven Law; Darren Foard; Marianna Fontana; Ana Martinez-Naharro; Carol Whelan; Julian D Gillmore; Helen J Lachmann; Sajitha Sachchithanantham; Shameem Mahmood; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Blood Cancer J       Date:  2021-06-21       Impact factor: 11.037

Review 8.  Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.

Authors:  Giovanni Palladini; Paolo Milani; Fabio Malavasi; Giampaolo Merlini
Journal:  Cells       Date:  2021-03-04       Impact factor: 6.600

9.  Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network).

Authors:  Vincenzo Sammartano; Elisabetta Antonioli; Gabriele Buda; Sara Ciofini; Veronica Candi; Ludovica Pengue; Maria Livia Del Giudice; Irene Attucci; Francesca Bacchiarri; Ubaldo Occhini; Maria Teresa Pirrotta; Federico Perfetto; Monica Bocchia; Alessandro Gozzetti
Journal:  J Pers Med       Date:  2022-03-17

Review 10.  Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist.

Authors:  Federico Perfetto; Mattia Zampieri; Carlo Fumagalli; Marco Allinovi; Francesco Cappelli
Journal:  Intern Emerg Med       Date:  2022-03-24       Impact factor: 5.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.